{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:00:49Z","timestamp":1792000849030,"version":"4.4.0"},"reference-count":189,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.<\/jats:p>","DOI":"10.6004\/jnccn.2025.0042","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:25:45Z","timestamp":1757507145000},"page":"403-418","source":"Crossref","is-referenced-by-count":67,"title":["Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"23","author":[{"given":"Al B.","family":"Benson","sequence":"first","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"D\u2019Angelica","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Abrams","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center | Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Akce","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Anaya","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Anders","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrakanth","family":"Are","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Aye","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Bachini","sequence":"additional","affiliation":[{"name":"Cholangiocarcinoma Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Baker","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Binder","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Brown","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Burgoyne","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Castellanos","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Cloyd","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Cullinan","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Franses","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Glazer","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Harris","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Iyer","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Jennings","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Kate","family":"Kelley","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajid","family":"Khan","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Levine","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Melstrom","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Palta","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Raman","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ronnekleiv-Kelly","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Stein","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Stephans","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Thanikachalam","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Turk","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Vauthey","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyo","family":"Yano","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Yopp","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Zhao","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Schonfeld","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Hochstetler","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA A Cancer J Clinicians","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA A Cancer J Clinicians 2025;75:10\u201345."},{"key":"B2","series-title":"Radiographics","first-page":"295","article-title":"Gallbladder carcinoma: radiologic-pathologic correlation","volume":"21","author":"Levy AD","year":"2001","unstructured":"Levy AD, Murakata LA, Rohrmann CA. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics 2001;21:295\u2013314; questionnaire, 549\u2013555."},{"key":"B3","series-title":"BMC Gastroenterol","first-page":"546","article-title":"The epidemiological trends of biliary tract cancers in the United States of America","volume":"22","author":"Jiang Y","year":"2022","unstructured":"Jiang Y, Jiang L, Li F,  The epidemiological trends of biliary tract cancers in the United States of America. BMC Gastroenterol 2022;22:546."},{"key":"B4","series-title":"Am J Clin Oncol","first-page":"306","article-title":"Trends in primary gallbladder cancer incidence and incidence-based mortality in the United States, 1973 to 2015","volume":"45","author":"Low SK","year":"2022","unstructured":"Low SK, Giannis D, Thuong ND,  Trends in primary gallbladder cancer incidence and incidence-based mortality in the United States, 1973 to 2015. Am J Clin Oncol 2022;45:306\u2013315."},{"key":"B5","series-title":"Int J Cancer","first-page":"1591","article-title":"Gallbladder cancer worldwide: geographical distribution and risk factors","volume":"118","author":"Randi G","year":"2006","unstructured":"Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006;118:1591\u20131602."},{"key":"B6","series-title":"CA Cancer J Clin","first-page":"349","article-title":"Epidemiology and molecular pathology of gallbladder cancer","volume":"51","author":"Lazcano-Ponce EC","year":"2001","unstructured":"Lazcano-Ponce EC, Miquel JF, Munoz N,  Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349\u2013364."},{"key":"B7","series-title":"Int J Cancer","first-page":"978","article-title":"Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends","volume":"147","author":"Miranda-Filho A","year":"2020","unstructured":"Miranda-Filho A, Pineros M, Ferreccio C,  Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends. Int J Cancer 2020;147:978\u2013989."},{"key":"B8","series-title":"AJR Am J Roentgenol","first-page":"819","article-title":"Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings","volume":"181","author":"Lim JH.","year":"2003","unstructured":"Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol 2003;181:819\u2013827."},{"key":"B9","series-title":"Nat Rev Gastroenterol Hepatol","first-page":"557","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales JM","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A,  Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557\u2013588."},{"key":"B10","series-title":"Oncologist","first-page":"874","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"Javle M","year":"2022","unstructured":"Javle M, Lee S, Azad NS,  Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017. Oncologist 2022;27:874\u2013883."},{"key":"B11","series-title":"Oncologist","first-page":"594","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha SK","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 2016;21:594\u2013599."},{"key":"B12","series-title":"J Natl Compr Canc Netw","first-page":"370","article-title":"Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States","volume":"16","author":"Mukkamalla SKR","year":"2018","unstructured":"Mukkamalla SKR, Naseri HM, Kim BM,  Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Canc Netw 2018;16:370\u2013376."},{"key":"B13","series-title":"World J Gastroenterol","first-page":"2591","article-title":"Adjuvant treatment in biliary tract cancer: to treat or not to treat?","volume":"18","author":"Cereda S","year":"2012","unstructured":"Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol 2012;18:2591\u20132596."},{"key":"B14","series-title":"J Egypt Natl Canc Inst","first-page":"1","article-title":"Adjuvant radiotherapy in the treatment of gall bladder carcinoma: what is the current evidence","volume":"28","author":"Mallick S","year":"2016","unstructured":"Mallick S, Benson R, Haresh KP,  Adjuvant radiotherapy in the treatment of gall bladder carcinoma: what is the current evidence. J Egypt Natl Canc Inst 2016;28:1\u20136."},{"key":"B15","series-title":"Lancet Oncol","first-page":"663","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose JN","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH,  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663\u2013673."},{"key":"B16","series-title":"J Clin Oncol","first-page":"2048","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater J","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH,  Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol 2022;40:2048\u20132057."},{"key":"B17","series-title":"Hepatology","first-page":"1540","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial","volume":"77","author":"Jeong H","year":"2023","unstructured":"Jeong H, Kim KP, Jeong JH,  Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology 2023;77:1540\u20131549."},{"key":"B18","series-title":"Cancer","first-page":"1685","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada T","year":"2002","unstructured":"Takada T, Amano H, Yasuda H,  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685\u20131695."},{"key":"B19","series-title":"Lancet","first-page":"195","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi K","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M,  Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 2023;401:195\u2013203."},{"key":"B20","series-title":"J Clin Oncol","first-page":"658","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline J","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A,  Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 2019;37:658\u2013667."},{"key":"B21","series-title":"Br J Surg","first-page":"192","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata T","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M,  Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018;105:192\u2013202."},{"key":"B22","series-title":"Cancer","first-page":"1689","article-title":"Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies","volume":"98","author":"Jarnagin WR","year":"2003","unstructured":"Jarnagin WR, Ruo L, Little SA,  Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689\u20131700."},{"key":"B23","series-title":"J Gastrointest Surg","first-page":"1666","article-title":"Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins","volume":"16","author":"Glazer ES","year":"2012","unstructured":"Glazer ES, Liu P, Abdalla EK,  Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg 2012;16:1666\u20131671."},{"key":"B24","series-title":"Cancer","first-page":"74","article-title":"The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts","volume":"124","author":"Tran Cao HS","year":"2018","unstructured":"Tran Cao HS, Zhang Q, Sada YH,  The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Cancer 2018;124:74\u201383."},{"key":"B25","series-title":"J Clin Oncol","first-page":"1934","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan AM","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30:1934\u20131940."},{"key":"B26","series-title":"Eur J Surg Oncol","first-page":"684","article-title":"Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis","volume":"46","author":"Rangarajan K","year":"2020","unstructured":"Rangarajan K, Simmons G, Manas D,  Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis. Eur J Surg Oncol 2020;46:684\u2013693."},{"key":"B27","series-title":"Radiat Oncol","first-page":"15","article-title":"A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"15","author":"Ren B","year":"2020","unstructured":"Ren B, Guo Q, Yang Y,  A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. Radiat Oncol 2020;15:15."},{"key":"B28","series-title":"BMC Cancer","first-page":"615","article-title":"Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis","volume":"15","author":"Ma N","year":"2015","unstructured":"Ma N, Cheng H, Qin B,  Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer 2015;15:615."},{"key":"B29","series-title":"Int J Radiat Oncol Biol Phys","first-page":"150","article-title":"Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience","volume":"75","author":"Gold DG","year":"2009","unstructured":"Gold DG, Miller RC, Haddock MG,  Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys 2009;75:150\u2013155."},{"key":"B30","series-title":"J Surg Oncol","first-page":"87","article-title":"Adjuvant chemoradiation therapy in gallbladder cancer","volume":"102","author":"Cho SY","year":"2010","unstructured":"Cho SY, Kim SH, Park S-J,  Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol 2010;102:87\u201393."},{"key":"B31","series-title":"Strahlenther Onkol","first-page":"388","article-title":"Postoperative chemoradiotherapy for gallbladder cancer","volume":"188","author":"Kim K","year":"2012","unstructured":"Kim K, Chie EK, Jang JY,  Postoperative chemoradiotherapy for gallbladder cancer. Strahlenther Onkol 2012;188:388\u2013392."},{"key":"B32","series-title":"Ann Surg Oncol","first-page":"2998","article-title":"Impact of chemotherapy and external-beam radiation therapy on outcomes among patients with resected gallbladder cancer: a multi-institutional analysis","volume":"23","author":"Kim Y","year":"2016","unstructured":"Kim Y, Amini N, Wilson A,  Impact of chemotherapy and external-beam radiation therapy on outcomes among patients with resected gallbladder cancer: a multi-institutional analysis. Ann Surg Oncol 2016;23:2998\u20133008."},{"key":"B33","series-title":"Int J Radiat Oncol Biol Phys","first-page":"178","article-title":"Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct","volume":"68","author":"Hughes MA","year":"2007","unstructured":"Hughes MA, Frassica DA, Yeo CJ,  Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178\u2013182."},{"key":"B34","series-title":"Int J Radiat Oncol Biol Phys","first-page":"148","article-title":"Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma","volume":"73","author":"Nelson JW","year":"2009","unstructured":"Nelson JW, Ghafoori AP, Willett CG,  Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009;73:148\u2013153."},{"key":"B35","series-title":"BMC Cancer","first-page":"345","article-title":"Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study","volume":"9","author":"Lim KH","year":"2009","unstructured":"Lim KH, Oh DY, Chie EK,  Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer 2009;9:345."},{"key":"B36","series-title":"Int J Radiat Oncol Biol Phys","first-page":"e853","article-title":"Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer","volume":"81","author":"Kim TH","year":"2011","unstructured":"Kim TH, Han SS, Park SJ,  Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 2011;81:e853\u2013859."},{"key":"B37","series-title":"Ann Surg Oncol","first-page":"3147","article-title":"Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone","volume":"15","author":"Borghero Y","year":"2008","unstructured":"Borghero Y, Crane CH, Szklaruk J,  Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008;15:3147\u20133156."},{"key":"B38","series-title":"Int J Radiat Oncol Biol Phys","first-page":"696","article-title":"Postoperative chemoradiotherapy for extrahepatic bile duct cancer","volume":"79","author":"Park JH","year":"2011","unstructured":"Park JH, Choi EK, Ahn SD,  Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2011;79:696\u2013704."},{"key":"B39","series-title":"J Clin Oncol","first-page":"2617","article-title":"SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef E","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB,  SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 2015;33:2617\u20132622."},{"key":"B40","series-title":"Ann Surg Oncol","first-page":"4896","article-title":"Adjuvant chemoradiation in resected biliary adenocarcinoma: evaluation of SWOG S0809 with a large national database","volume":"31","author":"Dominguez DA","year":"2024","unstructured":"Dominguez DA, Wong P, Chen YJ,  Adjuvant chemoradiation in resected biliary adenocarcinoma: evaluation of SWOG S0809 with a large national database. Ann Surg Oncol 2024;31:4896\u20134904."},{"key":"B41","series-title":"Radiat Oncol","first-page":"41","article-title":"Concurrent capecitabine and upper abdominal radiation therapy is well tolerated","volume":"1","author":"Das P","year":"2006","unstructured":"Das P, Wolff RA, Abbruzzese JL,  Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol 2006;1:41."},{"key":"B42","series-title":"Am J Clin Oncol","first-page":"234","article-title":"A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma","volume":"28","author":"Lin LL","year":"2005","unstructured":"Lin LL, Picus J, Drebin JA,  A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol 2005;28:234\u2013241."},{"key":"B43","series-title":"J Clin Oncol","first-page":"4627","article-title":"Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer","volume":"29","author":"Wang SJ","year":"2011","unstructured":"Wang SJ, Lemieux A, Kalpathy-Cramer J,  Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 2011;29:4627\u20134632."},{"key":"B44","series-title":"Anticancer Res","first-page":"5621","article-title":"Postoperative radiotherapy for gallbladder cancer","volume":"34","author":"Jeong Y","year":"2014","unstructured":"Jeong Y, Park JH, Lee YJ,  Postoperative radiotherapy for gallbladder cancer. Anticancer Res 2014;34:5621\u20135629."},{"key":"B45","series-title":"Pract Radiat Oncol","first-page":"28","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO Clinical Practice Guideline","volume":"12","author":"Apisarnthanarax S","year":"2022","unstructured":"Apisarnthanarax S, Barry A, Cao M,  External beam radiation therapy for primary liver cancers: an ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2022;12:28\u201351."},{"key":"B46","series-title":"Cancer Sci","first-page":"497","article-title":"Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma","volume":"108","author":"Fukuda K","year":"2017","unstructured":"Fukuda K, Okumura T, Abei M,  Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci 2017;108:497\u2013503."},{"key":"B47","series-title":"J Hepatol","first-page":"603","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial","volume":"74","author":"Kim TH","year":"2021","unstructured":"Kim TH, Koh YH, Kim BH,  Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol 2021;74:603\u2013612."},{"key":"B48","series-title":"J Clin Oncol","first-page":"219","article-title":"Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis","volume":"34","author":"Tao R","year":"2016","unstructured":"Tao R, Krishnan S, Bhosale PR,  Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016;34:219\u2013226."},{"key":"B49","series-title":"Hepatology","first-page":"659","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus CL","year":"2023","unstructured":"Bowlus CL, Arrive L, Bergquist A,  AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2023;77:659\u2013702."},{"key":"B50","series-title":"HPB (Oxford)","first-page":"418","article-title":"Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study","volume":"12","author":"Williams KJ","year":"2010","unstructured":"Williams KJ, Picus J, Trinkhaus K,  Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford) 2010;12:418\u2013426."},{"key":"B51","series-title":"Gut Liver","first-page":"298","article-title":"Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study","volume":"3","author":"Park J","year":"2009","unstructured":"Park J, Kim MH, Kim KP,  Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3:298\u2013305."},{"key":"B52","series-title":"NEJM Evid","first-page":"EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh DY","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S,  Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1:EVIDoa2200015."},{"key":"B53","series-title":"Lancet Gastroenterol Hepatol","first-page":"694","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh DY","year":"2024","unstructured":"Oh DY, He AR, Bouattour M,  Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol 2024;9:694\u2013704."},{"key":"B54","series-title":"Lancet","first-page":"1853","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley RK","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C,  Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853\u20131865."},{"key":"B55","series-title":"Ann Oncol","first-page":"593","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius B","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden PO,  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593\u2013600."},{"key":"B56","series-title":"J Clin Oncol","first-page":"4581","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma A","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK,  Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010;28:4581\u20134586."},{"key":"B57","series-title":"Oncologist","first-page":"415","article-title":"Systemic therapy for biliary tract cancers","volume":"13","author":"Hezel AF","year":"2008","unstructured":"Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008;13:415\u2013423."},{"key":"B58","series-title":"Discov Med","first-page":"41","article-title":"Toward personalized treatment of advanced biliary tract cancers","volume":"14","author":"Geynisman DM","year":"2012","unstructured":"Geynisman DM, Catenacci DV. Toward personalized treatment of advanced biliary tract cancers. Discov Med 2012;14:41\u201357."},{"key":"B59","series-title":"Br J Cancer","first-page":"896","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel F","year":"2007","unstructured":"Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896\u2013902."},{"key":"B60","series-title":"Jpn J Clin Oncol","first-page":"843","article-title":"A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer","volume":"37","author":"Yonemoto N","year":"2007","unstructured":"Yonemoto N, Furuse J, Okusaka T,  A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007;37:843\u2013851."},{"key":"B61","series-title":"Ann Oncol","first-page":"478","article-title":"Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial","volume":"15","author":"Kornek GV","year":"2004","unstructured":"Kornek GV, Schuell B, Laengle F,  Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004;15:478\u2013483."},{"key":"B62","series-title":"Eur J Cancer","first-page":"398","article-title":"A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial","volume":"41","author":"Ducreux M","year":"2005","unstructured":"Ducreux M, Van Cutsem E, Van Laethem JL,  A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005;41:398\u2013403."},{"key":"B63","series-title":"N Engl J Med","first-page":"1273","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle J","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH,  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273\u20131281."},{"key":"B64","series-title":"Br J Cancer","first-page":"469","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka T","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A,  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010;103:469\u2013474."},{"key":"B65","series-title":"J Clin Oncol","first-page":"262","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip JM","year":"2022","unstructured":"Phelip JM, Desrame J, Edeline J,  Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study. J Clin Oncol 2022;40:262\u2013271."},{"key":"B66","series-title":"Lancet Oncol","first-page":"690","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca A","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS,  Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021;22:690\u2013701."},{"key":"B67","series-title":"Autops Case Rep","first-page":"e2019087","article-title":"FOLFIRI as second-line treatment of metastatic biliary tract cancer patients","volume":"9","author":"Caparica R","year":"2019","unstructured":"Caparica R, Lengele A, Bekolo W, Hendlisz A. FOLFIRI as second-line treatment of metastatic biliary tract cancer patients. Autops Case Rep 2019;9:e2019087."},{"key":"B68","series-title":"World J Gastrointest Oncol","first-page":"83","article-title":"Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers","volume":"12","author":"Mizrahi JD","year":"2020","unstructured":"Mizrahi JD, Gunchick V, Mody K,  Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World J Gastrointest Oncol 2020;12:83\u201391."},{"key":"B69","series-title":"Eur J Cancer","first-page":"288","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi IS","year":"2021","unstructured":"Choi IS, Kim KH, Lee JH,  A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy. Eur J Cancer 2021;154:288\u2013295."},{"key":"B70","series-title":"Lancet Oncol","first-page":"1560","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo C","year":"2021","unstructured":"Yoo C, Kim KP, Jeong JH,  Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021;22:1560\u20131572."},{"key":"B71","series-title":"JAMA Oncol","first-page":"692","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung J","year":"2023","unstructured":"Hyung J, Kim I, Kim KP,  Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial. JAMA Oncol 2023;9:692\u2013699."},{"key":"B72","series-title":"Lancet Gastroenterol Hepatol","first-page":"734","article-title":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial","volume":"9","author":"Vogel A","year":"2024","unstructured":"Vogel A, Saborowski A, Wenzel P,  Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2024;9:734\u2013744."},{"key":"B73","series-title":"Br J Cancer","first-page":"1516","article-title":"A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer","volume":"90","author":"Doval DC","year":"2004","unstructured":"Doval DC, Sekhon JS, Gupta SK,  A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516\u20131520."},{"key":"B74","series-title":"Ann Oncol","first-page":"279","article-title":"Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma","volume":"16","author":"Thongprasert S","year":"2005","unstructured":"Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005;16:279\u2013281."},{"key":"B75","series-title":"Ann Oncol","first-page":"vii73","article-title":"Gemcitabine and cisplatin for inoperable and\/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell\u2019Italia Meridionale (GOIM)","volume":"17","author":"Giuliani F","year":"2006","unstructured":"Giuliani F, Gebbia V, Maiello E,  Gemcitabine and cisplatin for inoperable and\/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell\u2019Italia Meridionale (GOIM). Ann Oncol 2006;17(Suppl 7):vii73\u201377."},{"key":"B76","series-title":"Cancer Chemother Pharmacol","first-page":"47","article-title":"Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas","volume":"61","author":"Lee J","year":"2008","unstructured":"Lee J, Kim TY, Lee MA,  Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol 2008;61:47\u201352."},{"key":"B77","series-title":"Dig Dis Sci","first-page":"564","article-title":"Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer","volume":"53","author":"Meyerhardt JA","year":"2008","unstructured":"Meyerhardt JA, Zhu AX, Stuart K,  Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008;53:564\u2013570."},{"key":"B78","series-title":"Br J Cancer","first-page":"862","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andre T","year":"2008","unstructured":"Andre T, Reyes-Vidal JM, Fartoux L,  Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862\u2013867."},{"key":"B79","series-title":"Br J Cancer","first-page":"848","article-title":"Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer","volume":"95","author":"Harder J","year":"2006","unstructured":"Harder J, Riecken B, Kummer O,  Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95:848\u2013852."},{"key":"B80","series-title":"Cancer Chemother Pharmacol","first-page":"371","article-title":"A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer","volume":"64","author":"Kim HJ","year":"2009","unstructured":"Kim HJ, Lee NS, Lee SC,  A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemother Pharmacol 2009;64:371\u2013377."},{"key":"B81","series-title":"Cancer Chemother Pharmacol","first-page":"641","article-title":"Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial","volume":"65","author":"Jang JS","year":"2010","unstructured":"Jang JS, Lim HY, Hwang IG,  Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 2010;65:641\u2013647."},{"key":"B82","series-title":"Cancer","first-page":"111","article-title":"Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial","volume":"103","author":"Alberts SR","year":"2005","unstructured":"Alberts SR, Al-Khatib H, Mahoney MR,  Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111\u2013118."},{"key":"B83","series-title":"J Clin Oncol","first-page":"2332","article-title":"Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial","volume":"23","author":"Knox JJ","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A,  Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332\u20132338."},{"key":"B84","series-title":"Cancer","first-page":"1307","article-title":"Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer","volume":"110","author":"Riechelmann RP","year":"2007","unstructured":"Riechelmann RP, Townsley CA, Chin SN,  Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007;110:1307\u20131312."},{"key":"B85","series-title":"J Clin Oncol","first-page":"3702","article-title":"Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research","volume":"26","author":"Koeberle D","year":"2008","unstructured":"Koeberle D, Saletti P, Borner M,  Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008;26:3702\u20133708."},{"key":"B86","series-title":"Cancer Chemother Pharmacol","first-page":"1595","article-title":"A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202","volume":"68","author":"Iqbal S","year":"2011","unstructured":"Iqbal S, Rankin C, Lenz HJ,  A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol 2011;68:1595\u20131602."},{"key":"B87","series-title":"JAMA Oncol","first-page":"1707","article-title":"Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial","volume":"4","author":"Sahai V","year":"2018","unstructured":"Sahai V, Catalano PJ, Zalupski MM,  Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4:1707\u20131712."},{"key":"B88","series-title":"Ann Oncol","first-page":"2824","article-title":"Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology","volume":"24","author":"Borbath I","year":"2013","unstructured":"Borbath I, Ceratti A, Verslype C,  Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology. Ann Oncol 2013;24:2824\u20132829."},{"key":"B89","series-title":"Br J Cancer","first-page":"702","article-title":"Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial","volume":"87","author":"Nehls O","year":"2002","unstructured":"Nehls O, Klump B, Arkenau HT,  Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002;87:702\u2013704."},{"key":"B90","series-title":"Br J Cancer","first-page":"309","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls O","year":"2008","unstructured":"Nehls O, Oettle H, Hartmann JT,  Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309\u2013315."},{"key":"B91","series-title":"Ann Oncol","first-page":"1115","article-title":"Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer","volume":"14","author":"Kim TW","year":"2003","unstructured":"Kim TW, Chang HM, Kang HJ,  Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115\u20131120."},{"key":"B92","series-title":"BMC Cancer","first-page":"121","article-title":"A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma","volume":"6","author":"Kobayashi K","year":"2006","unstructured":"Kobayashi K, Tsuji A, Morita S,  A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer 2006;6:121."},{"key":"B93","series-title":"Ann Oncol","first-page":"788","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim ST","year":"2019","unstructured":"Kim ST, Kang JH, Lee J,  Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 2019;30:788\u2013795."},{"key":"B94","series-title":"Br J Cancer","first-page":"1650","article-title":"Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer","volume":"92","author":"Rao S","year":"2005","unstructured":"Rao S, Cunningham D, Hawkins RE,  Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005;92:1650\u20131654."},{"key":"B95","series-title":"Anticancer Res","first-page":"771","article-title":"Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study","volume":"26","author":"Yamashita Y","year":"2006","unstructured":"Yamashita Y, Taketomi A, Fukuzawa K,  Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study. Anticancer Res 2006;26:771\u2013775."},{"key":"B96","series-title":"Br J Cancer","first-page":"1846","article-title":"Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials","volume":"101","author":"Wagner AD","year":"2009","unstructured":"Wagner AD, Buechner-Steudel P, Moehler M,  Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer 2009;101:1846\u20131852."},{"key":"B97","series-title":"Ann Oncol","first-page":"3061","article-title":"A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma","volume":"24","author":"Sohal DP","year":"2013","unstructured":"Sohal DP, Mykulowycz K, Uehara T,  A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol 2013;24:3061\u20133065."},{"key":"B98","series-title":"Eur J Cancer","first-page":"3125","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler M","year":"2014","unstructured":"Moehler M, Maderer A, Schimanski C,  Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer 2014;50:3125\u20133135."},{"key":"B99","series-title":"J Clin Oncol","first-page":"3094","article-title":"Nanoliposomal irinotecan with fluorouracil and leucovorin or gemcitabine plus cisplatin in advanced cholangiocarcinoma: a phase II study of the AIO Hepatobiliary-YMO cancer groups (NIFE-AIO-YMO HEP-0315)","volume":"42","author":"Ettrich TJ","year":"2024","unstructured":"Ettrich TJ, Modest DP, Sinn M,  Nanoliposomal irinotecan with fluorouracil and leucovorin or gemcitabine plus cisplatin in advanced cholangiocarcinoma: a phase II study of the AIO Hepatobiliary-YMO cancer groups (NIFE-AIO-YMO HEP-0315). J Clin Oncol 2024;42:3094\u20133104."},{"key":"B100","series-title":"J Clin Oncol","first-page":"3218","article-title":"Bevacizumab erlotinib switch maintenance in chemo-responsive advanced gallbladder and cholangiocarcinoma (BEER BTC): a multicenter, open-label, randomized, phase II trial","volume":"42","author":"Ramaswamy A","year":"2024","unstructured":"Ramaswamy A, Bhargava P, Srinivas S,  Bevacizumab erlotinib switch maintenance in chemo-responsive advanced gallbladder and cholangiocarcinoma (BEER BTC): a multicenter, open-label, randomized, phase II trial. J Clin Oncol 2024;42:3218\u20133227."},{"key":"B101","series-title":"Int J Radiat Oncol Biol Phys","first-page":"654","article-title":"Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma","volume":"81","author":"Ghafoori AP","year":"2011","unstructured":"Ghafoori AP, Nelson JW, Willett CG,  Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2011;81:654\u2013659."},{"key":"B102","series-title":"Surg Oncol Clin N Am","first-page":"941","article-title":"Palliative and postoperative radiotherapy in biliary tract cancer","volume":"11","author":"Macdonald OK","year":"2002","unstructured":"Macdonald OK, Crane CH. Palliative and postoperative radiotherapy in biliary tract cancer. Surg Oncol Clin N Am 2002;11:941\u2013954."},{"key":"B103","series-title":"Oncology (Williston Park)","first-page":"873","article-title":"Radiation therapy in the treatment of cholangiocarcinoma","volume":"20","author":"Czito BG","year":"2006","unstructured":"Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006;20:873\u2013884."},{"key":"B104","series-title":"J Clin Oncol","first-page":"460","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong TS","year":"2016","unstructured":"Hong TS, Wo JY, Yeap BY,  Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460\u2013468."},{"key":"B105","series-title":"J Clin Oncol","first-page":"657","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"Tse RV","year":"2008","unstructured":"Tse RV, Hawkins M, Lockwood G,  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657\u2013664."},{"key":"B106","series-title":"Br J Radiol","first-page":"20180688","article-title":"Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review","volume":"92","author":"Frakulli R","year":"2019","unstructured":"Frakulli R, Buwenge M, Macchia G,  Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review. Br J Radiol 2019;92:20180688."},{"key":"B107","series-title":"BMC Cancer","first-page":"568","article-title":"Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma","volume":"13","author":"Moureau-Zabotto L","year":"2013","unstructured":"Moureau-Zabotto L, Turrini O, Resbeut M,  Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer 2013;13:568."},{"key":"B108","series-title":"Strahlenther Onkol","first-page":"496","article-title":"Primary carcinoma of the gallbladder: role of external beam radiation therapy in patients with locally advanced tumor","volume":"172","author":"Uno T","year":"1996","unstructured":"Uno T, Itami J, Aruga M,  Primary carcinoma of the gallbladder: role of external beam radiation therapy in patients with locally advanced tumor. Strahlenther Onkol 1996;172:496\u2013500."},{"key":"B109","series-title":"Neoplasia","first-page":"100910","article-title":"Genomics driven precision oncology in advanced biliary tract cancer improves survival","volume":"42","author":"Kumar-Sinha C","year":"2023","unstructured":"Kumar-Sinha C, Vats P, Tran N,  Genomics driven precision oncology in advanced biliary tract cancer improves survival. Neoplasia 2023;42:100910."},{"key":"B110","series-title":"Cancer","first-page":"1995","article-title":"Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings","volume":"126","author":"Maynard H","year":"2020","unstructured":"Maynard H, Stadler ZK, Berger MF,  Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings. Cancer 2020;126:1995\u20132002."},{"key":"B111","series-title":"JAMA Oncol","first-page":"230","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder NJ","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L,  Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol 2021;7:230\u2013237."},{"key":"B112","series-title":"JCO Precis Oncol","first-page":"PO.18.00183","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura R","year":"2018","unstructured":"Okamura R, Boichard A, Kato S,  Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol 2018;2018:PO.18.00183."},{"key":"B113","series-title":"J Hepatol","first-page":"170","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca A","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol 2020;73:170\u2013185."},{"key":"B114","series-title":"N Engl J Med","first-page":"731","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S,  Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731\u2013739."},{"key":"B115","series-title":"Lancet Oncol","first-page":"271","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L,  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271\u2013282."},{"key":"B116","series-title":"Ann Oncol","first-page":"S787","article-title":"Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon BJ","year":"2023","unstructured":"Solomon BJ, Drilon A, Lin JJ,  Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial. Ann Oncol 2023;34(Suppl 2):S787\u2013788."},{"key":"B117","series-title":"Science","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","unstructured":"Le DT, Durham JN, Smith KN,  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409\u2013413."},{"key":"B118","series-title":"Chin Clin Oncol","first-page":"62","article-title":"Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva VW","year":"2016","unstructured":"Silva VW, Askan G, Daniel TD,  Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol 2016;5:62."},{"key":"B119","series-title":"Cancers (Basel)","first-page":"558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"Rizzo A","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers (Basel) 2021;13:558."},{"key":"B120","series-title":"Lancet Oncol","first-page":"1353","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J,  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353\u20131365."},{"key":"B121","series-title":"Int J Cancer","first-page":"2190","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul SA","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M,  Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020;147:2190\u20132198."},{"key":"B122","series-title":"Cancer Med","first-page":"4699","article-title":"Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer","volume":"8","author":"Zang YS","year":"2019","unstructured":"Zang YS, Dai C, Xu X,  Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med 2019;8:4699\u20134708."},{"key":"B123","series-title":"Cell","first-page":"1327","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169:1327\u20131341.e23."},{"key":"B124","series-title":"J Gastrointest Oncol","first-page":"652","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg BA","year":"2019","unstructured":"Weinberg BA, Xiu J, Lindberg MR,  Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol 2019;10:652\u2013662."},{"key":"B125","series-title":"Oncologist","first-page":"787","article-title":"Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns","volume":"26","author":"Israel MA","year":"2021","unstructured":"Israel MA, Danziger N, McGregor KA,  Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns. Oncologist 2021;26:787\u2013796."},{"key":"B126","series-title":"J Clin Oncol","first-page":"1","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA,  Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1\u201310."},{"key":"B127","series-title":"Ann Oncol","first-page":"929","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio M","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L,  Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929\u2013938."},{"key":"B128","series-title":"Nat Med","first-page":"744","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick JK","year":"2019","unstructured":"Sicklick JK, Kato S, Okamura R,  Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 2019;25:744\u2013750."},{"key":"B129","series-title":"JAMA Netw Open","first-page":"e2341165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andre T","year":"2023","unstructured":"Andre T, Berton D, Curigliano G,  Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw Open 2023;6:e2341165."},{"key":"B130","series-title":"J Immunother Cancer","first-page":"e008872","article-title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","volume":"12","author":"Schenker M","year":"2024","unstructured":"Schenker M, Burotto M, Richardet M,  Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. J Immunother Cancer 2024;12:e008872."},{"key":"B131","series-title":"JAMA Oncol","first-page":"888","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim RD","year":"2020","unstructured":"Kim RD, Chung V, Alese OB,  A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 2020;6:888\u2013894."},{"key":"B132","series-title":"Sci Rep","first-page":"12348","article-title":"High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer","volume":"10","author":"Ahn S","year":"2020","unstructured":"Ahn S, Lee JC, Shin DW,  High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep 2020;10:12348."},{"key":"B133","series-title":"Lancet Oncol","first-page":"1234","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah V","year":"2020","unstructured":"Subbiah V, Lassen U, Elez E,  Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234\u20131243."},{"key":"B134","series-title":"Gastroenterology","first-page":"1021","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen JB","year":"2012","unstructured":"Andersen JB, Spee B, Blechacz BR,  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:1021\u20131031.e15."},{"key":"B135","series-title":"Mod Pathol","first-page":"1028","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert B","year":"2014","unstructured":"Goeppert B, Frauenschuh L, Renner M,  BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol 2014;27:1028\u20131034."},{"key":"B136","series-title":"Oncotarget","first-page":"2839","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo M","year":"2014","unstructured":"Simbolo M, Fassan M, Ruzzenente A,  Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 2014;5:2839\u20132852."},{"key":"B137","series-title":"J Clin Oncol","first-page":"3895","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial Subprotocol H","volume":"38","author":"Salama AKS","year":"2020","unstructured":"Salama AKS, Li S, Macrae ER,  Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial Subprotocol H. J Clin Oncol 2020;38:3895\u20133904."},{"key":"B138","series-title":"Cell Rep","first-page":"2780","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar F","year":"2017","unstructured":"Farshidfar F, Zheng S, Gingras MC,  Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 2017;18:2780\u20132794."},{"key":"B139","series-title":"J Clin Pathol","first-page":"403","article-title":"Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets","volume":"69","author":"Lee H","year":"2016","unstructured":"Lee H, Wang K, Johnson A,  Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol 2016;69:403\u2013408."},{"key":"B140","series-title":"N Engl J Med","first-page":"228","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal L","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A,  Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388:228\u2013239."},{"key":"B141","series-title":"Cancer Discov","first-page":"326","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman IM","year":"2021","unstructured":"Silverman IM, Hollebecque A, Friboulet L,  Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov 2021;11:326\u2013339."},{"key":"B142","series-title":"ESMO Open","first-page":"103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel A","year":"2024","unstructured":"Vogel A, Sahai V, Hollebecque A,  An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open 2024;9:103488."},{"key":"B143","series-title":"Lancet Oncol","first-page":"925","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant S","year":"2023","unstructured":"Pant S, Schuler M, Iyer G,  Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 2023;24:925\u2013935."},{"key":"B144","series-title":"J Clin Oncol","first-page":"Abstract 427","article-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: interim results from the phase 2 study FIDES-01","volume":"40","author":"Javle MM","year":"2022","unstructured":"Javle MM, Abou-Alfa GK, Macarulla T,  Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: interim results from the phase 2 study FIDES-01. J Clin Oncol 2022;40(Suppl):Abstract 427."},{"key":"B145","series-title":"Future Oncol","first-page":"2057","article-title":"Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma","volume":"17","author":"Aguado-Fraile E","year":"2021","unstructured":"Aguado-Fraile E, Tassinari A, Ishii Y,  Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. Future Oncol 2021;17:2057\u20132074."},{"key":"B146","series-title":"J Gastrointest Oncol","first-page":"751","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe AN","year":"2019","unstructured":"Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol 2019;10:751\u2013765."},{"key":"B147","series-title":"Cancer","first-page":"3838","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle M","year":"2016","unstructured":"Javle M, Bekaii-Saab T, Jain A,  Biliary cancer: utility of next-generation sequencing for clinical management. Cancer 2016;122:3838\u20133847."},{"key":"B148","series-title":"Lancet Oncol","first-page":"796","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa GK","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM,  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:796\u2013807."},{"key":"B149","series-title":"JAMA Oncol","first-page":"1669","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu AX","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM,  Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7:1669\u20131677."},{"key":"B150","series-title":"Oncol Res Treat","first-page":"20","article-title":"ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway","volume":"44","author":"Jacobi O","year":"2021","unstructured":"Jacobi O, Ross JS, Goshen-Lago T,  ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway. Oncol Res Treat 2021;44:20\u201327."},{"key":"B151","series-title":"J Clin Pathol","first-page":"500","article-title":"Overexpression\/amplification of HER-2\/neu is uncommon in hepatocellular carcinoma","volume":"58","author":"Xian ZH","year":"2005","unstructured":"Xian ZH, Zhang SH, Cong WM,  Overexpression\/amplification of HER-2\/neu is uncommon in hepatocellular carcinoma. J Clin Pathol 2005;58:500\u2013503."},{"key":"B152","series-title":"Hum Pathol","first-page":"9","article-title":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","volume":"105","author":"Hiraoka N","year":"2020","unstructured":"Hiraoka N, Nitta H, Ohba A,  Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Hum Pathol 2020;105:9\u201319."},{"key":"B153","series-title":"Cancer Metastasis Rev","first-page":"141","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy S","year":"2017","unstructured":"Galdy S, Lamarca A, McNamara MG,  HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev 2017;36:141\u2013157."},{"key":"B154","series-title":"Cancer Metastasis Rev","first-page":"157","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan M","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D,  HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 2015;34:157\u2013164."},{"key":"B155","series-title":"PLoS One","first-page":"e115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi CR","year":"2014","unstructured":"Churi CR, Shroff R, Wang Y,  Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9:e115383."},{"key":"B156","series-title":"Gastrointest Cancer Res","first-page":"42","article-title":"Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa I","year":"2014","unstructured":"Roa I, de Toro G, Schalper K,  Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res 2014;7:42\u201348."},{"key":"B157","series-title":"Cancer Chemother Pharmacol","first-page":"777","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan RK","year":"2009","unstructured":"Ramanathan RK, Belani CP, Singh DA,  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64:777\u2013783."},{"key":"B158","series-title":"Oncology","first-page":"175","article-title":"HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib","volume":"82","author":"Peck J","year":"2012","unstructured":"Peck J, Wei L, Zalupski M,  HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology 2012;82:175\u2013179."},{"key":"B159","series-title":"J Clin Oncol","first-page":"536","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth JD","year":"2018","unstructured":"Hainsworth JD, Meric-Bernstam F, Swanton C,  Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 2018;36:536\u2013542."},{"key":"B160","series-title":"Nature","first-page":"189","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman DM","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H,  HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018;554:189\u2013194."},{"key":"B161","series-title":"Lancet Oncol","first-page":"1558","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam F","year":"2022","unstructured":"Meric-Bernstam F, Beeram M, Hamilton E,  Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol 2022;23:1558\u20131570."},{"key":"B162","series-title":"J Clin Oncol","first-page":"47","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam F","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A,  Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42:47\u201358."},{"key":"B163","series-title":"J Clin Oncol","first-page":"3207","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba A","year":"2024","unstructured":"Ohba A, Morizane C, Kawamoto Y,  Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial. J Clin Oncol 2024;42:3207\u20133217."},{"key":"B164","series-title":"J Hematol Oncol","first-page":"58","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle M","year":"2015","unstructured":"Javle M, Churi C, Kang HC,  HER2\/neu-directed therapy for biliary tract cancer. J Hematol Oncol 2015;8:58."},{"key":"B165","series-title":"Lancet Oncol","first-page":"1290","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle M","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS,  Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22:1290\u20131300."},{"key":"B166","series-title":"J Clin Oncol","first-page":"3228","article-title":"Pertuzumab plus trastuzumab in patients with biliary tract cancer with ERBB2\/3 alterations: results from the Targeted Agent and Profiling Utilization Registry study","volume":"42","author":"Cannon TL","year":"2024","unstructured":"Cannon TL, Rothe M, Mangat PK,  Pertuzumab plus trastuzumab in patients with biliary tract cancer with ERBB2\/3 alterations: results from the Targeted Agent and Profiling Utilization Registry study. J Clin Oncol 2024;42:3228\u20133237."},{"key":"B167","series-title":"Cancers (Basel)","first-page":"161","article-title":"Feasibility of HER2-targeted therapy in advanced biliary tract cancer: a prospective pilot study of trastuzumab biosimilar in combination with gemcitabine plus cisplatin","volume":"13","author":"Jeong H","year":"2021","unstructured":"Jeong H, Jeong JH, Kim KP,  Feasibility of HER2-targeted therapy in advanced biliary tract cancer: a prospective pilot study of trastuzumab biosimilar in combination with gemcitabine plus cisplatin. Cancers (Basel) 2021;13:161."},{"key":"B168","series-title":"J Clin Oncol","first-page":"5569","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura Y","year":"2023","unstructured":"Nakamura Y, Mizuno N, Sunakawa Y,  Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. J Clin Oncol 2023;41:5569\u20135578."},{"key":"B169","series-title":"Lancet Oncol","first-page":"772","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding JJ","year":"2023","unstructured":"Harding JJ, Fan J, Oh DY,  Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol 2023;24:772\u2013782."},{"key":"B170","series-title":"Nat Commun","first-page":"630","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding JJ","year":"2023","unstructured":"Harding JJ, Piha-Paul SA, Shah RH,  Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun 2023;14:630."},{"key":"B171","series-title":"J Clin Oncol","first-page":"800","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-naive human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","volume":"42","author":"Ostwal V","year":"2024","unstructured":"Ostwal V, Mandavkar S, Bhargava P,  Trastuzumab plus gemcitabine-cisplatin for treatment-naive human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB). J Clin Oncol 2024;42:800\u2013807."},{"key":"B172","series-title":"N Engl J Med","first-page":"1207","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong DS","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH,  KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020;383:1207\u20131217."},{"key":"B173","series-title":"N Engl J Med","first-page":"2371","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis F","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK,  Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021;384:2371\u20132381."},{"key":"B174","series-title":"J Clin Oncol","first-page":"4097","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab TS","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI,  Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol 2023;41:4097\u20134106."},{"key":"B175","series-title":"Cancer","first-page":"1979","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal L","year":"2017","unstructured":"Goyal L, Zheng H, Yurgelun MB,  A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 2017;123:1979\u20131988."},{"key":"B176","series-title":"Ann Oncol","first-page":"1416","article-title":"A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors","volume":"25","author":"Pant S","year":"2014","unstructured":"Pant S, Saleh M, Bendell J,  A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol 2014;25:1416\u20131421."},{"key":"B177","series-title":"N Engl J Med","first-page":"54","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa GK","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL,  Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54\u201363."},{"key":"B178","series-title":"Ann Transl Med","first-page":"1099","article-title":"Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report","volume":"8","author":"Zhou Y","year":"2020","unstructured":"Zhou Y, Lizaso A, Mao X,  Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report. Ann Transl Med 2020;8:1099."},{"key":"B179","series-title":"Nat Med","first-page":"1640","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Cassier PA, Siena S,  Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat Med 2022;28:1640\u20131645."},{"key":"B180","series-title":"PLoS One","first-page":"e15640","article-title":"Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma","volume":"6","author":"Gu TL","year":"2011","unstructured":"Gu TL, Deng X, Huang F,  Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011;6:e15640."},{"key":"B181","series-title":"Am J Surg Pathol","first-page":"1550","article-title":"A novel NIPBL-NACC1 gene fusion is characteristic of the cholangioblastic variant of intrahepatic cholangiocarcinoma","volume":"45","author":"Argani P","year":"2021","unstructured":"Argani P, Palsgrove DN, Anders RA,  A novel NIPBL-NACC1 gene fusion is characteristic of the cholangioblastic variant of intrahepatic cholangiocarcinoma. Am J Surg Pathol 2021;45:1550\u20131560."},{"key":"B182","series-title":"Virchows Arch","first-page":"33","article-title":"Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas","volume":"477","author":"Augustin J","year":"2020","unstructured":"Augustin J, Gabignon C, Scriva A,  Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas. Virchows Arch 2020;477:33\u201345."},{"key":"B183","series-title":"JCO Precis Oncol","first-page":"e2100245","article-title":"Landscape of KRASG12C, associated genomic alterations, and interrelation with Immuno-oncology biomarkers in KRAS-mutated cancers","volume":"6","author":"Salem ME","year":"2022","unstructured":"Salem ME, El-Refai SM, Sha W,  Landscape of KRASG12C, associated genomic alterations, and interrelation with Immuno-oncology biomarkers in KRAS-mutated cancers. JCO Precis Oncol 2022;6:e2100245."},{"key":"B184","series-title":"Ann Oncol","first-page":"1269","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck JE","year":"2022","unstructured":"Berchuck JE, Facchinetti F, DiToro DF,  The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol 2022;33:1269\u20131283."},{"key":"B185","series-title":"Clin Cancer Res","first-page":"1988","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato S","year":"2017","unstructured":"Kato S, Subbiah V, Marchlik E,  RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res 2017;23:1988\u20131997."},{"key":"B186","series-title":"Lancet Oncol","first-page":"1261","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B,  Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 2022;23:1261\u20131273."},{"key":"B187","series-title":"Cancer","first-page":"902","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun W","year":"2019","unstructured":"Sun W, Patel A, Normolle D,  A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer 2019;125:902\u2013909."},{"key":"B188","series-title":"Cancer","first-page":"3464","article-title":"A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer","volume":"126","author":"Kim RD","year":"2020","unstructured":"Kim RD, Sanoff HK, Poklepovic AS,  A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer 2020;126:3464\u20133470."},{"key":"B189","series-title":"Ann Oncol","first-page":"1169","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols A","year":"2020","unstructured":"Demols A, Borbath I, Van den Eynde M,  Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol 2020;31:1169\u20131177."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/9\/article-p403.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/9\/article-p403.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/9\/article-p403.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:25:46Z","timestamp":1757507146000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/9\/article-p403.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":189,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.0042","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}